• Glibenclamide, Metformin & Pioglitazone Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical stability of the three highly reactive APIs.

    Active IngredientStrengthPrimary Clinical Function
    Glibenclamide USP/Ph.Eur.5 mgThe Secretagogue (Micro-Dose): Triggers rapid, potent insulin release from the pancreas to control acute post-prandial (after-meal) glucose spikes.
    Pioglitazone (as Hydrochloride) USP/Ph.Eur.15 mgThe Sensitizer (Micro-Dose): Reverses deep cellular insulin resistance in skeletal muscle and adipose tissue.
    Metformin Hydrochloride USP/Ph.Eur.500 mg (IR or ER)The Hepatic Anchor (Macro-Dose): Provides baseline suppression of liver glucose production. Frequently formulated in a sustained-release matrix to minimize severe GI side effects.
    ExcipientsMicrocrystalline Cellulose / Croscarmellose Sodium / Hypromellose / Magnesium Stearate / Premium Opadry FilmDiluent / Superdisintegrant / Binder (ER Polymer) / Lubricant (Engineered utilizing elite multi-stage geometric dilution to guarantee that the lethal 5mg micro-dose of Glibenclamide is flawlessly and evenly distributed throughout the massive 500mg Metformin matrix)

    *Pack Sizes: 10×10 Alu-Alu Blisters (Optimized specifically for strict, chronic diabetic dispensing regimens).

  • Imatinib tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical stability of the mesylate salt.

    Active IngredientStrengthPrimary Clinical Function
    Imatinib (as Mesylate) USP/Ph.Eur.100 mgPediatric & Titration Standard: Base therapeutic unit utilized for weight-based pediatric leukemia dosing, or for highly precise adult dose adjustments during acute hematological toxicity.
    Imatinib (as Mesylate) USP/Ph.Eur.400 mgGlobal Adult Oncology Standard: High-efficacy adult maintenance dose, typically taken once daily for the chronic phase of CML, or twice daily for accelerated phases and GIST.
    ExcipientsMicrocrystalline Cellulose / Crospovidone / Hypromellose / Colloidal Silicon Dioxide / Magnesium Stearate / Premium Iron-Oxide FilmDiluent / Superdisintegrant / Binder / Glidant / Heavy Film-Coating (Engineered specifically to lock the cytotoxic API safely inside the tablet, completely preventing handler and pharmacist exposure to the carcinogenic dust)

    *Pack Sizes: 10×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic oncology dispensing regimens).

  • Ivabradine HCL Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical stability of the highly hygroscopic hydrochloride salt.

    Active IngredientStrengthPrimary Clinical Function
    Ivabradine (as Hydrochloride) USP/Ph.Eur.5 mgInitiation / Titration Standard: Base therapeutic unit utilized twice daily for the safe initiation of therapy, allowing the cardiologist to monitor resting heart rate before upward titration.
    Ivabradine (as Hydrochloride) USP/Ph.Eur.7.5 mgGlobal Maintenance Standard: High-efficacy adult maintenance dose to strictly maintain the resting heart rate between 50 and 60 beats per minute.
    ExcipientsLactose Monohydrate / Maize Starch / Maltodextrin / Colloidal Silicon Dioxide / Magnesium Stearate / Premium Opadry FilmDiluent / Binder / Glidant / Lubricant / Film-Coating (Engineered specifically using precise geometric dilution to ensure the micro-dose API is flawlessly distributed, preventing accidental bradycardia from “hot spots” in a poorly blended generic tablet)

    *Pack Sizes: 10×10 Blisters or Bottles of 56 (Optimized specifically for strict 28-day chronic cardiology dispensing regimens).